Abstract
The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 289-300 |
| Number of pages | 12 |
| Journal | Cell Stem Cell |
| Volume | 4 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 3 2009 |
| Externally published | Yes |
ASJC Scopus subject areas
- Cell Biology
- Molecular Medicine
- Genetics
Fingerprint Dive into the research topics of 'Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation'. Together they form a unique fingerprint.
Cite this
Kiuru, M. H., Boyer, J. L., O'Connor, T. P., & Crystal, R. G. (2009). Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation. Cell Stem Cell, 4(4), 289-300. https://doi.org/10.1016/j.stem.2009.03.010